Acute Monoblastic Leukemia with a Single Chromosomal Rearrangement Involving Breakpoints on Chromosomes 8 and 16,46, XX, t(8;16)(p11 ; pl3)

1987 ◽  
Vol 78 (1) ◽  
pp. 1-5 ◽  
Author(s):  
H.S. Juneja ◽  
F.F.B. Elder ◽  
S. Rajaraman
Keyword(s):  
Chromosomal Rearrangement ◽  
Acute Monoblastic Leukemia

Acute Monoblastic Leukemia with t(11;17)(q23;q21): Fusion of the KMT2A(MLL) and MLLT6(AF17) Genes

2019 ◽  
Vol 9 (4) ◽  
pp. 258
Author(s):  
Cheon-Gang Park ◽  
Seon-Ho Mun ◽  
A-Jin Lee ◽  
Chang-Ho Jeon ◽  
Hun Suk Suh ◽  
...  
Keyword(s):  
Acute Monoblastic Leukemia

Molecular mechanisms of chromosomal rearrangement during primate evolution

2008 ◽  
Vol 16 (1) ◽  
pp. 41-56 ◽  
Author(s):  
Hildegard Kehrer-Sawatzki ◽  
David N. Cooper
Keyword(s):  
Chromosomal Rearrangement ◽  
Molecular Mechanisms ◽  
Primate Evolution

scholarly journals Activator-independent gene expression in Neurospora crassa

Genetics ◽  
1996 ◽  
Vol 142 (2) ◽  
pp. 417-423
Author(s):  
Wayne K Versaw ◽  
Robert L Metzenberg
Keyword(s):  
Gene Expression ◽  
Neurospora Crassa ◽  
Chromosomal Rearrangement ◽  
Position Effect ◽  
Upstream Region ◽  
Phosphorus Metabolism ◽  
Position Effects ◽  
Cis Acting ◽  
Independent Gene ◽  
Acting Mechanism

Abstract A transgenic position effect that causes activator-independent gene expression has been described previously for three Neurospora crassa phosphate-repressible genes. We report analogous findings for two additional positively regulated genes, qa-2  + and ars-1  +, indicating that such position effects are not limited to genes involved in phosphorus metabolism. In addition, we have characterized a number of mutants that display activator-independent gene expression. Each of these mutants contains a chromosomal rearrangement with one breakpoint located in the 5’-upstream region of the affected gene. This suggests that the rearrangements are associated with activator-independent gene expression and that these cis-acting mutations may represent a position effect similar to that responsible for rendering some transgenes independent of their transcriptional activators. We suggest that positively regulated genes in N.  crassa are normally held in a transcriptionally repressed state by a cis-acting mechanism until specifically activated. Disruption of this cis-acting mechanism, either by random integration of a gene by transformation or by chromosomal rearrangement, renders these genes independent or partly independent of the transcriptional activator on which they normally depend.

A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia

1984 ◽  
Vol 16 (1) ◽  
pp. 83-90 ◽  
Author(s):  
James B. Bussel ◽  
Peter G. Steinherz ◽  
Denis R. Miller ◽  
Margaret W. Hilgartner
Keyword(s):  
Acute Monoblastic Leukemia

Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia

Blood ◽  
2001 ◽  
Vol 98 (12) ◽  
pp. 3492-3494 ◽  
Author(s):  
Udomsak Bunworasate ◽  
Hilal Arnouk ◽  
Hans Minderman ◽  
Kieran L. O'Loughlin ◽  
Sheila N. J. Sait ◽  
...  
Keyword(s):  
Myelodysplastic Syndrome ◽  
Bone Marrow Cells ◽  
Tritiated Thymidine ◽  
Flow Cytometric Analysis ◽  
Refractory Anemia ◽  
Laboratory Findings ◽  
Flow Cytometric ◽  
Acute Monoblastic Leukemia ◽  
Leukemia Cutis ◽  
Marrow Cells

Abstract Acute monoblastic leukemia (acute myeloid leukemia [AML], French-American-British type M5a) with leukemia cutis developed in a patient 6 weeks after the initiation of erythropoietin (EPO) therapy for refractory anemia with ringed sideroblasts. AML disappeared from both marrow and skin after the discontinuation of EPO. Multiparameter flow cytometric analysis of bone marrow cells demonstrated coexpression of the EPO receptor with CD45 and CD13 on the surface of blasts. The incubation of marrow cells with EPO, compared to without, resulted in 1.3- and 1.6-fold increases, respectively, in tritiated thymidine incorporation and bromodeoxyuridine incorporation into CD13+ cells. Clinical and laboratory findings were consistent with the EPO-dependent transformation of myelodysplastic syndrome (MDS) to AML. It is concluded that leukemic transformation in patients with MDS treated with EPO may be EPO-dependent and that management should consist of the discontinuation of EPO followed by observation, if clinically feasible.

Sign in / Sign up

Export Citation Format

Share Document